2023 Novo Holdings Bioindustrial Investments Team Annual Review/Business Update
Established the Novo Holdings Bioindustrial Investments team,…
BII welcomes innovative smartRNA project to Bio Studio program
BioInnovation Institute (BII), an international non-profit foundation,…
Novo Holdings Joins €30M Series A Financing for Asgard Therapeutics, Leader In In Vivo Cell Reprogramming To Treat Cancer
Financing to advance first platform designed to reprogram…
Novo Holdings Portfolio Company Amolyt Pharma Enters into Definitive Agreement to be Acquired by AstraZeneca
Deal value up to US$1.05 billion
Novo Holdings co-led Series…
Asgard Therapeutics announces €30 million Series A financing to advance its first-in-class in vivo cell reprogramming platform for immuno-oncology
Co-led by RV Invest and Johnson & Johnson Innovation…
Mission Therapeutics raises £25.2 million to progress clinical candidates in the area of mitophagy
• Developing novel therapeutics which enhance the removal of…
Biocomposites announces approval of STIMULAN in Brazil as an antibiotic carrier for treating bacterial infection
STIMULAN, when mixed with antibiotics, can be used for the…
Novo Holdings reports Total Income and Investment Returns of DKK 31 billion (€4.2 billion) for 2023. Total Assets grow by 38% to DKK 1,114 billion (€149 billion)
Copenhagen, Denmark – Novo Holdings today announced its financial…
US FDA grants Orphan Drug Designation for iOnctura’s first-in-class autotaxin cancer therapy
Autotaxin inhibitor, IOA-289, recently received the proposed…
BioInnovation Institute provides financial support as six promising companies enter the Venture House program
BioInnovation Institute (BII), an international non-profit foundation…
Novo Nordisk Foundation awarded more than DKK 9.1 billion for purposes benefitting society in 2023
Focusing its support on science, education, innovation and development…
Calliditas announces an additional seven year orphan drug exclusivity period for TARPEYO®
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm:…
Women in Life Science Denmark (WiLD) to host network meeting in collaboration with DANISH BIO to promote equity in the Danish life science industry
Keynote speaker Margrethe Vestager, EU commissioner and EVP of…
Asceneuron Expands Scientific Advisory Board with World Leading Experts in Neurodegenerative Diseases
Significant appointments of industry and academic experts…
Heidelberg Pharma to Present First Efficacy Data on HDP-101 and Data from Proprietary ADC Technology Platform at AACR Meeting 2024
Ladenburg, Germany, 6 March 2024 – Heidelberg Pharma AG (FSE:…
Novo Holdings Venture Investments 2023 Newsletter: A record year advancing innovative therapies for patients
18 new portfolio investments
Five portfolio companies…
Fibrocor Therapeutics enters into research and development collaboration with McQuade Center for Strategic Research and Development to advance Alport Syndrome program
Agreement includes a single digit million US$ upfront payment…
Collaboration between BRAIN Biotech and AMSilk: Protein engineering successfully improves structural proteins for performance materials
First patent application registered
BRAIN Biotech relies…
Ariceum Therapeutics announces opening of new state-of-the-art laboratory in Berlin providing infrastructure for radiopharmaceutical development activities
Berlin, Germany, 5 March 2024 – Ariceum Therapeutics (Ariceum),…
We’d love to hear from you.
For more information about Optimum Strategic Communications, please get in touch.
We are specialists with an indepth understanding of how to communicate complex science to investors and corporate stakeholders. We help companies on their journey as they grow and have been trusted by hundreds of clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York